Trasylol (Aprotinin, BAYA0128) + Placebo

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Blood Loss, Surgical

Conditions

Blood Loss, Surgical

Trial Timeline

Dec 1, 2005 → Mar 1, 2007

NCT ID

NCT00306137

About Trasylol (Aprotinin, BAYA0128) + Placebo

Trasylol (Aprotinin, BAYA0128) + Placebo is a phase 3 stage product being developed by Bayer for Blood Loss, Surgical. The current trial status is terminated. This product is registered under clinical trial identifier NCT00306137. Target conditions include Blood Loss, Surgical.

What happened to similar drugs?

7 of 16 similar drugs in Blood Loss, Surgical were approved

Approved (7) Terminated (5) Active (7)

✅micafungin + voriconazoleAstellas PharmaApproved

✅Bunazosin + Doxazosin + ValsartinEisaiApproved

✅AliskirenNovartisApproved

✅Aliskiren and HCTZNovartisApproved

✅Aspirin 100 mg + PlaceboBayerApproved

✅Hemostatic MatrixBaxterApproved

✅losartan potassium + Comparator: PlaceboOrganonApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00327379	Phase 3	Terminated	Feb 27, 2006	Mar 1, 2007	Blood Loss, Surgical
NCT00306137	Phase 3	Terminated	Dec 1, 2005	Mar 1, 2007	Blood Loss, Surgical
NCT00306150	Phase 3	Terminated	Dec 1, 2005	Mar 1, 2007	Blood Loss, Surgical
NCT00668031	Phase 3	Completed	Feb 1, 2005	Jan 1, 2006	Blood Loss, Surgical

Competing Products

20 competing products in Blood Loss, Surgical

See all competitors

Product	Company	Stage	Hype Score
micafungin + voriconazole	Astellas Pharma	Approved	35
Cefiderocol	Shionogi	Phase 2	35
Bunazosin + Doxazosin + Valsartin	Eisai	Approved	43
Pegfilgrastim	Kyowa Kirin	Phase 2	35
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2	35
Metoprolol Succinate + Hydrochlorothiazide	AstraZeneca	Phase 3	40
AZD6140 + Placebo	AstraZeneca	Phase 1	29
NKTR-118 + moxifloxacin + Placebo	AstraZeneca	Phase 1	29
MEDI-551	AstraZeneca	Phase 1	29
Ecallantide + Cyklokapron(R)	Merck	Phase 2	35
Daptomycin	Merck	Phase 2	35
ecallantide + placebo	Merck	Phase 2	35
MK0859	Merck	Phase 1	29
Ecallantide + Placebo	Merck	Phase 2	27
HSC835	Novartis	Phase 2	35
Aliskiren	Novartis	Approved	35
Aliskiren and HCTZ	Novartis	Approved	43
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine	Novartis	Phase 2	35